Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.
2 reports, 2 independent
Updated Jul 23
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Also in this story
- Skyclarys announced its international expansion into Brazil and the U.K. on July 22, 2025.
- Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
- TMO expanded a strategic partnership with Sanofi on August 28, 2025.
- Sales of products including Vivitrol, Aristada, and Lybalvi increased due to strong market demand and new prescriptions.
The entities involved
-
Biogen
American multinational biotechnology company
Coverage
Newest first; wire copies grouped- GlobeNewswireAmyotrophic Lateral Sclerosis (ALS) Market Forecast Report 2025-2034 | Advancements in Therapeutics and Approved Medications Such as Riluzole, Edaravone, and Nuedexta Drive Growth The ALS treatment m
- Insider MonkeyRBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abraha